Larimar Therapeutics (LRMR) Liabilities and Shareholders Equity (2016 - 2020)
Historic Liabilities and Shareholders Equity for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $114.0 million.
- Larimar Therapeutics' Liabilities and Shareholders Equity rose 2268.35% to $114.0 million in Q3 2020 from the same period last year, while for Dec 2020 it was $313.1 million, marking a year-over-year increase of 30.72%. This contributed to the annual value of $5.2 million for FY2019, which is 9572.86% down from last year.
- According to the latest figures from Q3 2020, Larimar Therapeutics' Liabilities and Shareholders Equity is $114.0 million, which was up 2268.35% from $125.5 million recorded in Q2 2020.
- In the past 5 years, Larimar Therapeutics' Liabilities and Shareholders Equity ranged from a high of $170.0 million in Q1 2016 and a low of $5.2 million during Q4 2019
- Its 5-year average for Liabilities and Shareholders Equity is $109.5 million, with a median of $110.2 million in 2019.
- Per our database at Business Quant, Larimar Therapeutics' Liabilities and Shareholders Equity soared by 3706.58% in 2018 and then tumbled by 9572.86% in 2019.
- Over the past 5 years, Larimar Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $131.6 million in 2016, then fell by 19.84% to $105.5 million in 2017, then increased by 15.4% to $121.8 million in 2018, then plummeted by 95.73% to $5.2 million in 2019, then surged by 2091.06% to $114.0 million in 2020.
- Its Liabilities and Shareholders Equity was $114.0 million in Q3 2020, compared to $125.5 million in Q2 2020 and $73.7 million in Q1 2020.